BofA Downgrades Onterris to Underperform From Neutral, Adjusts Price Target to $18 From $31

Bank of America downgraded Onterris, Inc. to Underperform from Neutral and cut its price target to $18 from $31, according to the note cited in the article. The stock is shown trading around $15.24 at the time of publication, with the article referencing Onterris’ recent earnings call.

Original reporting
Published Aug 6, 2026, 1:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 2:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMarket movers
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ONT
Relevance
7/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

A downgrade to Underperform plus a sharp PT cut typically increases sell-side caution and can trigger additional downgrades or estimate revisions from other analysts.

02

Market read

This is a single-name sell-side action with a large price-target reduction, which can drive short-term positioning and sentiment.

03

What to watch

The article body omits BofA’s rationale, so traders should verify whether the change is driven by estimates, margins, balance-sheet risk, or one-off items before trading aggressively.

Relevance 7/10Novelty 5/10Timing: today, pre-market analyst downgrade and price-target cut

Background

The text is a headline-style analyst note: BofA downgrades Onterris and reduces its price target materially.

Market effects

Could modestly weigh on sentiment for similarly valued small/mid-cap names if the downgrade reflects broader risk concerns, but no sector specifics are provided.

No clear regional spillover described beyond the single-name analyst action.

No global macro or cross-border catalyst mentioned.

Counterpoint

If the downgrade is based on valuation rather than deteriorating fundamentals, the stock could stabilize if upcoming earnings or guidance contradict the bearish thesis.

Key entities

  • Onterris

    Subject of the analyst downgrade and price-target reduction cited in the article.

  • BofA

    The firm issuing the downgrade and price-target adjustment.

Related articles

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

$ONTHighAI 8/10

Why is Oxford Nanopore Technologies stock rallying today?

Oxford Nanopore Technologies' stock rose 6.6% after its interim results showed improved profitability, with gross margin expanding to 62.2% and adjusted EBITDA losses halving. The company also announced a new licensing deal expected to generate $20 million in fees. Berenberg maintained a Buy rating but lowered its price target to £2.00. The stock is still below its 52-week high of 215.6p.

$ONTHigh

Onterris, Inc. (ONT): Results of Operations and Financial Condition

Onterris, Inc. (ONT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Onterris Reports Second Quarter Results, Updates Full-Year 2026 Guidance, and Announces Board-led Strategic Review Process Updates Date and Time of Conference Call to Today, Wednesday, August 5, at 5:30 p.m. Eastern Time Second Quarter 2026 Highlights (comparisons to

$PLUSMed

PageGroup & Oxford Nanopore: Markets live

PageGroup shares rose over 11% after it reported Q2 gross profit of £198m, down 0.2% year on year but ahead of analyst expectations, and said it sees signs of market normalisation. ME Group International gained about 11% after interim results showed flat £154m sales. Plus500 shares fell on weaker cash margin, and Oxford Nanopore dropped 12% after H1 sales missed expectations at £116.5m.